Skip to main
WVE

WVE Stock Forecast & Price Target

WVE Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

WAVE Life Sciences Ltd is a clinical-stage biotechnology company with a robust RNA medicines platform, PRISM, which integrates various RNA-targeting modalities, positioning it well for addressing both rare and prevalent diseases. Management forecasts enhanced therapeutic effects across its programs, with significant milestones expected in the next few years, including accelerated regulatory engagement for WVE-006 and a new drug application submission for WVE-N531. Positive developments in clinical trials and changes in revenue assumptions have led to an upward adjustment in price targets, reflecting increased confidence in the company's future revenue potential and overall financial outlook.

Bears say

WAVE Life Sciences Ltd faces significant financial challenges, as evidenced by a net loss of $53.2 million, or $0.30 per share, in the latest quarter, alongside substantial research and development expenses totaling $53 million. The company’s ability to raise capital on favorable terms is critical; failure to secure adequate funding could hinder its product launches and overall stock performance. Furthermore, the competitive landscape in which WAVE operates poses additional risks, as existing programs may struggle to achieve projected revenue estimates due to both technical evaluations in clinical trials and market dynamics.

WVE has been analyzed by 14 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Wave Life Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Wave Life Sciences (WVE) Forecast

Analysts have given WVE a Buy based on their latest research and market trends.

According to 14 analysts, WVE has a Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Wave Life Sciences (WVE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.